文献速递心力衰竭与心肌病心律失常

年龄与非缺血性收缩性心衰一级预防ICD的结局

Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.
PubMed 文献 · Circulation · 2017-09-06

该研究为DANISH试验的预设亚组分析,纳入1116例非缺血性收缩性心衰患者,评估ICD植入与年龄的关系。结果显示ICD与生存的关联随年龄增长线性下降,≤70岁患者全因死亡风险降低(HR 0.70,95%CI 0.51-0.96,P=0.03),>70岁患者无获益(HR 1.05,95%CI 0.68-1.62,P=0.84)。

要点

  • 非缺血性收缩性心衰患者中,ICD获益随年龄增长而减弱。
  • ≤70岁患者ICD与全因死亡降低相关(HR 0.70)。
  • >70岁患者ICD与全因死亡无显著相关(HR 1.05)。

核心结论

  • 在非缺血性收缩性心衰患者中,ICD植入与生存的关联随年龄增长呈线性下降。
  • 本研究中≤70岁作为ICD植入年龄切点使总体人群生存率最高。

研究设计与样本

  • DANISH试验的预设亚组分析,纳入全部1116例患者,按年龄评估ICD植入与死亡率的关系。
  • 采用非参数选择影响曲线估算最佳年龄切点,并用χ2检验比较年龄切点上下患者的死亡模式。

主要发现

  • 研究人群中位年龄63岁(范围21-84岁)。
  • ICD与死亡率的关系随年龄呈线性变化(HR 1.03,95%CI 1.003-1.06,P=0.03)。
  • ≤70岁患者ICD与全因死亡降低相关(HR 0.70,95%CI 0.51-0.96,P=0.03),>70岁患者无显著相关(HR 1.05,95%CI 0.68-1.62,P=0.84)。
  • ≤70岁患者心脏性猝死率1.8(95%CI 1.3-2.5)、非猝死率2.7(95%CI 2.1-3.5)每100患者年;>70岁患者分别为1.6(95%CI 0.8-3.2)和5.4(95%CI 3.7-7.8)每100患者年,两组死亡模式差异有统计学意义(P=0.01)。

关键数值与推荐

  • 最佳ICD植入年龄切点为≤70岁。
  • ≤70岁患者ICD与全因死亡降低相关(HR 0.70,95%CI 0.51-0.96,P=0.03)。
  • >70岁患者ICD与全因死亡无显著相关(HR 1.05,95%CI 0.68-1.62,P=0.84)。

临床怎么用

  • 对非缺血性收缩性心衰患者考虑一级预防ICD时,应结合年龄评估获益可能性。
  • ≤70岁患者可能从ICD植入中获得生存获益,>70岁患者需谨慎选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The DANISH study (Danish Study to Assess the Efficacy of ICDs [Implantable Cardioverter Defibrillators] in Patients With Non-Ischemic Systolic Heart Failure on Mortality) did not demonstrate an overall effect on all-cause mortality with ICD implantation. However, the prespecified subgroup analysis suggested a possible age-dependent association between ICD implantation and mortality with survival benefit seen only in the youngest patients. The nature of this relationship between age and outcome of a primary prevention ICD in patients with nonischemic systolic heart failure warrants further investigation. METHODS: All 1116 patients from the DANISH study were included in this prespecified subgroup analysis. We assessed the relationship between ICD implantation and mortality by age, and an optimal age cutoff was estimated nonparametrically with selection impact curves. Modes of death were divided into sudden cardiac death and nonsudden death and compared between patients younger and older than this age cutoff with the use of χ2 analysis. RESULTS: Median age of the study population was 63 years (range, 21-84 years). There was a linearly decreasing relationship between ICD and mortality with age (hazard ratio [HR], 1.03; 95% confidence interval [CI], 1.003-1.06; P=0.03). An optimal age cutoff for ICD implantation was present at ≤70 years. There was an association between reduced all-cause mortality and ICD in patients ≤70 years of age (HR, 0.70; 95% CI, 0.51-0.96; P=0.03) but not in patients >70 years of age (HR, 1.05; 95% CI, 0.68-1.62; P=0.84). For patients ≤70 years old, the sudden cardiac death rate was 1.8 (95% CI, 1.3-2.5) and nonsudden death rate was 2.7 (95% CI, 2.1-3.5) events per 100 patient-years, whereas for patients >70 years old, the sudden cardiac death rate was 1.6 (95% CI, 0.8-3.2) and nonsudden death rate was 5.4 (95% CI, 3.7-7.8) events per 100 patient-years. This difference in modes of death between the 2 age groups was statistically significant (P=0.01). CONCLUSIONS: In patients with systolic heart failure not caused by ischemic heart disease, the association between the ICD and survival decreased linearly with increasing age. In this study population, an age cutoff for ICD implantation at ≤70 years yielded the highest survival for the population as a whole. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00542945.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Elming MB, Nielsen JC, Haarbo J, et al. Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. Circulation. 2017. PMID: 28877914. doi:10.1161/CIRCULATIONAHA.117.028829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。